CVS Health Revises Its Full-year 2024 Adjusted EPS Guidance To $6.40-$6.65 From At Least $7.00 versus Consensus Of $6.98
Portfolio Pulse from Benzinga Newsdesk
CVS Health has revised its full-year 2024 adjusted EPS guidance to $6.40-$6.65 from at least $7.00, which is below the consensus of $6.98. The revision is due to continued pressure in the Health Care Benefits segment, partially offset by strong performance in the Health Services and Pharmacy & Consumer Wellness segment.
August 07, 2024 | 10:33 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
CVS Health has lowered its full-year 2024 adjusted EPS guidance to $6.40-$6.65 from at least $7.00, which is below the consensus of $6.98. This revision is due to ongoing challenges in the Health Care Benefits segment, though it is partially offset by strong performance in the Health Services and Pharmacy & Consumer Wellness segment.
The downward revision of the EPS guidance is a negative indicator for CVS Health's stock price in the short term. The pressure in the Health Care Benefits segment outweighs the strong performance in other segments, leading to a lower-than-expected EPS forecast.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100